Abcam, ab255694, Anti-DLL3 antibody [EPR22592-18] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal DLL3 antibody. Carrier free. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human, Mouse samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR22592-18,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Human,
Applications:Flow Cyt (Intra), ICC/IF, WB, IP, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:The mouse recommendation is based on the IHC-P results. We do not guarantee WB for mouse.

Product details:
ab255694 is the carrier-free version of
ab229902
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DLL3 also known as Delta-like protein 3 is a member of the Delta/Serrate/Jagged family. This protein has a molecular mass of approximately 64 kDa. Scientists find DLL3 expression primarily in the Golgi apparatus of cells. In healthy tissues DLL3 is mostly present in the central nervous system whereas in abnormal conditions it appears in certain types of cancer cells. The detection of DLL3 expression commonly performed using IHC (immunohistochemistry) highlights its potential as a biomarker in pathological studies.
Biological function summary
DLL3 functions mainly in the modulation of the Notch signaling pathway. It does not activate this pathway but acts as an inhibitor blocking Notch ligand activation on adjacent cells. DLL3's role involves binding directly to Notch receptors altering cellular differentiation and growth processes. Despite being related to the Delta/Serrate/LAG-2 family DLL3 exhibits unique characteristics in its interactions forming part of a regulatory complex different from its family members.
Pathways
DLL3 engages importantly in the Notch signaling pathway affecting important cellular communications that regulate development and differentiation. Its interaction with proteins of the Notch family specifically the Notch receptors highlights its inhibitory role. Additionally DLL3 intersects with the Wnt signaling pathway though indirect influencing its output by modulating availability of pathway regulators.
DLL3 has significant implications in cancer notably small cell lung cancer (SCLC) and neuroendocrine tumors. Researchers associate increased DLL3 expression with aggressive tumor behavior and poor prognosis. The protein also shows relevance in congenital disorders such as spondylocostal dysostosis where abnormal DLL3 function leads to vertebral segmentation defects. In these contexts DLL3 often relates to proteins involved in the disruption of normal signaling cascades impacting both tumor progression and developmental anomalies.